Business
Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium
Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\n MINNEAPOLIS, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, today announced that an abstract describing Phase 1 clinical data for SBP-101 has been accepted for poster presentation January 24, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, being held January 23-25 in San Francisco. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) a metabolic pathway of critical importance in multiple tumor types. Sun BioPharma also announced that Arthur J. Fratamico, RPh, MBA recently joined its Board of Directors.  Mr. Fratamico is an experienced business development executive with 25 years of experience in the biopharmaceutical industry, including corporate development, commercial strategy and financing. With this addition, Sun BioPharma’s board now totals six members. “I’m delighted to welcome Art to the Sun BioPharma board,” said Michael T. Cullen, MD, MBA, CEO, President and Executive Chairman of Sun BioPharma. “Art brings highly relevant experience, and we look forward to the benefit of his expertise in business development and strategy at this significant stage of the company.” Mr. Fratamico has served as Chief Business Officer of Galera Therapeutics since January 2017. Prior to joining Galera, Mr. Fratamico served as Chief Business Officer of Vitae Pharmaceuticals until its sale to Allergan. He previously held similar executive roles with a number of biotechnology companies, including MGI Pharma and Gemin X, leading their business development efforts and facilitating the sales of both Gemin X Pharmaceuticals and MGI Pharma. He has also served in several senior marketing, product planning and new product development positions. Mr. Fratamico earned a bachelor’s degree in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from Drexel University, and is a registered pharmacist. Poster Presentation Information:Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma.Friday, January 24, 2020, 12:00 PM to 1:30 PM and 4:30 PM to 5:30 PM...